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by Elsevier B.V. This is an open accesAbstract The bacillus Calmette Guerin (BCG) vaccine contains live attenuated Mycobacte-
rium bovis bacteria. There is a long-standing controversy surrounding the efficacy of BCG
against TB and whether it should be used. BCG is associated with significant adverse effects,
including life-threatening disseminated BCG infection in children with primary immunodefi-
ciency (PID). Here, we present a case report of an infant diagnosed with severe combined im-
munodeficiency disease and disseminated BCGitis. There are no clear guidelines for the most
suitable treatment for disseminated BCG disease. Hematopoietic stem cell transplantation
(HSCT) is needed in urgent cases. BCGitis is known to exacerbate clinically after HSCT while
immune reconstitution occurs. During this time, rapidly expanding peripheral T cells of the
graft result in a severe inflammatory response, lymphadenitis, multiple abscesses, and sepsis,
and fatal multiple organ failure is possible. Modification of the transplant procedure and the
use of immunosuppressive medications and prednisolone to treat cytokine reactions at the
time of overwhelming immune reconstitution are usually necessary.
Copyright ª 2014, King Faisal Specialist Hospital & Research Centre (General Organization),
Saudi Arabia. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
An eight-month-old Saudi girl was referred to King Faisal
Specialist Hospital & Research Centre (KFSH&RC) to rule
out primary immunodeficiency disease.sal Specialist Hospital & Research
fshrc.edu.sa.
f King Faisal Specialist Hospital &
14.11.005
al Specialist Hospital & Research C
s article under the CC BY-NC-ND lThe patient was born via normal spontaneous vaginal
delivery with a birth weight of 2.8 kg. At the age of 4
weeks, she began to have recurrent chest infections,
chronic diarrhea and poor weight gain, which necessitated
two hospital admissions. At the age of five months, sheCentre, P.O. Box 3354, MBC 58, Riyadh 11211, Saudi Arabia. Tel.:
Research Centre (General Organization), Saudi Arabia.
entre (General Organization), Saudi Arabia. Production and hosting
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
90 H. Al-Mousapresented to the local hospital with persistent fever,
swelling, tenderness and discharge from the BCG vaccine
site associated with generalized lymphadenopathy, hep-
atosplenomegaly and a scattered macular rash. A lymph
node aspiration, bronchoalveolar lavage and skin biopsy
revealed acid fast bacilli; as a result, she was started on
isoniazid, rifampicin, ethambutol and clarithromycin. In
addition, bronchoalveolar lavage identified a Pneumocystis
jiroveci pneumonia infection, which was treated with
trimethoprrin-sulfamethoxazole therapy. The parents of
the patient were cousins with a family history of a sibling
dying at ten months of age due to suspected meningitis.
Based on the family history and clinical findings, the
patient was referred to KFSH&RC to rule out primary im-
munodeficiency disease. On examination, she was chroni-
cally ill and emaciated, with a weight of 4.8 kg. She had
generalized lymphadenopathy involving both axilla with
lymph node sizes of 3  3 cm with small subclavicular and
inguinal lymph node enlargement. There was swelling at
the BCG site of 0.5  0.5 cm and a scattered macular rash
over her entire body. She was afebrile with a respiratory
rate of 32 breaths per minute and good air entry with
scattered crepitation. Abdominal examination revealed a
palpable spleen 2 cm below the costal margin.
Laboratory investigation as shown in Table 1 showed se-
vere lymphopenia, an absence of T & B cells via lymphocyte
phenotyping and a poor lymphocytic response to mitogen
stimulation; these signs are suggestive of severe combined
immunodeficiency. Lymph node and skin biopsy confirmed
the presence of acid fast bacilli, and mycobacterium bovis
was isolated. The isolate was susceptible to isoniazid,
rifampicin, ciprofloxacin, amikacin and clarithromycin. CT
scan of the chest and abdomen showed multiple cold ab-
scesses and necrotic lymph nodes of the chest and abdomen.
Skeletal survey revealed multiple small lytic lesions distrib-
uted in the upper and lower extremities, including both
hands and feet, associated with a periosteal reaction of the
proximal tibia, fibula, proximal humeri and both femurs;
there were also pathological fractures (Fig. 1).Table 1 Laboratory data.
At diagnosis
(8 months of age)
White cell count/mm3 2750
Lymphocytes/mm3 50
Neutrophils/mm3 2200
Monocytes/mm3 300
IgG (g/L) 13.3
IgA (g/L) 0.82
IgM (g/L) 0.66
CD3/mm3 3
CD4/mm3 2
CD8/mm3 1
CD19/mm3 <1
CD56/16/mm3 59
Lymphocytes chimerism (%) e
Myeloid chimerism (%) e
PHA (C.P.M.  103) 28,512
Con A (C.P.M.  103) 17,332Based on the family history, clinical findings, and
immunological work-up, the patient was diagnosed with
severe combined immunodeficiency with disseminated
BCGitis. She was started on anti-TB therapy including,
isoniazid, rifampicin, ethambutol, ciprofloxacin and clari-
thromycin. Patient underwent hematopoetic Stem Cell
Transplantation (HSCT) using hers father as a donor , who
was HLA matched for risk of graft vs host disease (GVHD)
and haploidentical for risk of rejection.
On the second week post HSCT, the patient started to
develop a persistent fever associated with a flare up of the
swelling at the BCG site. She also had an enlarged Lt axillary
lymph node with abscesses requiring lymph node excision
and drainage; this was associated with generalized pap-
ulonodular skin lesions over the entire body (Fig. 2). Lymph
node and skin biopsy also confirmed the presence of acid fast
bacilli. The severe inflammatory response post HSCT
dictated the initiation of steroid treatment to control the
post engraftment inflammatory response to disseminated
BCGitis. The patient’s symptoms of fever, skin lesions and
persistent lymphadenopathy lasted for one year post HSCT,
at which time her immune system controlled the dissemi-
nated BCG infection. She completed a 2-year course of anti-
TB therapy. Currently, she is 30 months post HSCT, she is no
longer taking anti-TB therapy, and she is on regular intrave-
nous immunoglobulin because she had no B-cell engraft-
ment. A chimerism study showed evidence of 100%
lymphocytes and 3.9% myeloid cell engraftment. The
detailed immune reconstitution post HSCT is shown in
Table 1.
2. Discussion
The bacillus Calmette Guerin (BCG) vaccine contains live
attenuated Mycobacterium bovis and is the only available
vaccine for TB disease [1e3]. There is a long-standing
controversy surrounding its efficacy against TB and whether
it should be used [4]. In addition to its low efficacy, BCG is
associated with significant adverse effects, including local2 years post
HSCT
Normal range
2770 6000e18000
1110 4000e12000
860 1000e6000
690 200e1200
7.5 3.5e12.4
0.32 0.4e1.2
<0.18 0.43e1.7
1082 3100e4800
667 2200e3300
404 1100e1700
<1 1100e1900
205 300e700
100 e
3.9 e
78,417 94935e171149
59,117 78011e133442
Figure 1 Multiple small bony lytic lesions with periosteal reaction.
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myelitis. Another important complication of BCG is a life-
threatening disseminated BCG infection. This complica-
tion has been noted in children with primary immunodefi-
ciency (PID), including severe combined immunodeficiency
(SCID), chronic granulomatous diseases (CGD), complete
DiGeorge syndrome (cDGS), acquired immune deficiency
syndrome (AIDS) and the Mendelian susceptibility to
mycobacterial disease (MSMD) (e.g., IFN-g receptor 1/2
deficiencies, IL-12/23 receptor b1 chain deficiency, IL-
12p40 deficiency, STAT1 deficiency and NEMO deficiency)
[5e13].
Severe combined immunodeficiency (SCID) is the most
severe form of primary immunodeficiency diseases and is
characterized by a block in T lymphocyte differentiation
that is variably associated with the abnormal development
of other lymphocyte lineages, i.e., B and NK lymphocytes
and, more rarely, myeloid lineages [14,15]. The clinical
presentation of SCID is fairly uniform and is characterized
by early onset and diverse infections. Oral candidiasis,Figure 2 Generalized papulonodular BCGitis skin lesions.persistent diarrhea with growth impairment and/or inter-
stitial pneumonitis are the most frequent infectious mani-
festations leading to the diagnosis of SCID [16]. Persistent
infections with opportunistic organisms lead to death in the
first two years of life, unless immune reconstitution can be
accomplished by hematopoietic stem cell transplantation
(HSCT) or gene therapy.
There are no clear guidelines on the most suitable
treatment for disseminated BCG disease [17,18]. Aggressive
therapy involving at least four anti-TB drugs is usually
needed. Furthermore, BCG vaccine strains differ in their
susceptibility pattern to antituberculous drugs, and this
should be considered when administering empirical ther-
apy. SCID should be considered a pediatric emergency, and
hematopoietic stem cell transplantation (HSCT) should be
performed on an urgent basis. BCGitis is known to exacer-
bate clinically after HSCT, while immune reconstitution
occurs. During this time, rapidly expanding peripheral T
cells of the graft result in a severe inflammatory response,
lymphadenitis, multiple abscesses, and sepsis, and fatal
multiple organ failure is possible. Modification of the
transplant procedure and the use of immunosuppressive
medications and prednisolone to treat cytokine reactions at
the time of overwhelming immune reconstitution are usu-
ally necessary.
The frequency of SCID throughout the world is estimated
to be 1 in 75,000e100,000 live births [19,20]. The high rate
of consanguinity in the Saudi population (56%) [21] pre-
disposes Saudi individuals to a high incidence of primary
immunodeficiency disorders. The estimated SCID incidence
in Saudi Arabia is 1 in 5000 live births, making this popu-
lation more vulnerable to BCG complications. The BCG
vaccine is part of the routine vaccination program for all
newborns in the country. Based on available data that
indicate that the BCG vaccine has low efficacy with serious
complications and the high incidence of primary immuno-
deficiency disorders among Saudi children, the need for
BCG vaccination in our community and the possible benefit
of postponing BCG vaccination until 12 months of age
should be evaluated. By 12 months of age, most congenital
92 H. Al-Mousaimmunodeficiency disorders are apparent, which would
allow BCG vaccination to be avoided in patients with such
disorders.
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